Rspondins as modulators of angiogenesis and vasculogenesis
AssigneeDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsChristof Niehrs, Olga Kazanskaya, Bisei Okawara
Life of this patent
Estimating the term…
Loading patent…
AssigneeDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsChristof Niehrs, Olga Kazanskaya, Bisei Okawara
Estimating the term…
The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 arc angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.
A method for inhibiting angiogenesis and/or vasculogenesis in a subject in need of such treatment comprising administering to the subject a therapeutically effective dose of an Rspondin2 antagonist, wherein the Rspondin2 antagonist is a nucleic acid molecule capable of inhibiting Rspondin2 translation, transcription, expression and/or activity.
Dependencies are inferred from the claim text.